Organization
Brown University - Lifespan Cancer Institute
27 abstracts
Abstract
NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC).Org: Lifespan Health System, Brown University - Lifespan Cancer Institute, Cancer Center at Brown University, Brown University Department of Family Medicine,
Abstract
Synergistic inhibition of CXCL8 following MRTX1133 treatment with ONC212 or 5-FU in KRAS G12D and G12V mutant CRC and PDAC cell lines.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
Durvalumab and consolidation SBRT following chemoradiation for stage III non-small cell lung cancer: A single institution pilot study.Org: Brown University - Lifespan Cancer Institute, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Warren Alpert Medical School of Brown University, Rhode Island Hospital,
Abstract
ITGB6 as an inhibitor of T-cell killing via modulation of paracrine TGFβ signaling in pancreatic ductal adenocarcinoma.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI,
Abstract
Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD).Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Brown University–ECOG-ACRIN Biostatistics Center, Brown University - Lifespan Cancer Institute, University of Massachusetts Lowell,
Abstract
Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.Org: Memorial Sloan Kettering Cancer Center, Mount Sinai Icahn School of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Yonsei Cancer Center, Yonsei University Health System, Brown University - Lifespan Cancer Institute,
Abstract
The Brown University cancer prevention & survivorship curriculum: A case study on program development in an internal medicine residency.Org: Brown University/Lifespan Hospitals, University of Texas MD Anderson Cancer Center, Yale University, Legorreta Cancer Center at Brown University, Brown University - Lifespan Cancer Institute,
Abstract
Pan-cancer analysis of natural killer (NK) cell infiltration in human malignancies: Molecular features and clinical implications.Org: Caris Life Sciences, Irving, TX, Barbara Ann Karmanos Cancer Institute, St. John's Cancer Institute, Santa Monica, CA, Brown University - Lifespan Cancer Institute, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Clinical Research Institute at Rambam, Rambam Medical Center,
Abstract
The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).Org: Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care, Penn State Milton S. Hershey Medical Center, Hershey, PA, Brown University - Lifespan Cancer Institute, West Cancer Center and Research Institute,
Abstract
A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).Org: Brown University - Lifespan Cancer Institute, Yale University, Rhode Island Hospital, Lifespan Oncology Clinical Research, Brown University Oncology Research Group,
Abstract
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Org: MD Anderson Cancer Center, Brown University - Lifespan Cancer Institute, Hospital de Clinicas de Porto Alegre, Samsung Medical Center, Pusan National University Hospital,
Abstract
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.Org: University of California Irvine School of Medicine, Barbara Ann Karmanos Cancer Institute, Lombardi Comprehensive Cancer Center, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care,
Abstract
BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).Org: Legorreta Cancer Center at Brown University, Lifespan Health System, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Brown University - Lifespan Cancer Institute,
Abstract
Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).Org: Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Dartmouth Geisel School of Medicine, Brown University - Lifespan Cancer Institute, University of California San Francisco,
Abstract
Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Highlands Oncology,
Abstract
GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.Org: Legorreta Cancer Center at Brown University, Providence, RI, Brown University - Lifespan Cancer Institute, NanoString Technologies, Inc., Seattle, WA,
Abstract
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Section of Hematology & Oncology, University of Chicago Medical Center, Dana-Farber Cancer Institute, Department of Internal Medicine, Seoul National University Bundang Hospital,
Abstract
A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.Org: Virginia Cancer Specialists, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
Tumor treating fields (TTFields) therapy skin safety and prevention strategy using a fractionated schema protocol (3-days on/1-day off), effect on skin adverse events.Org: Banner MD Anderson Cancer Center, Geisinger Health System Department of Pathology, Brown University - Lifespan Cancer Institute,
Abstract
Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Cancer Center at Brown University,
Abstract
Pilot trial of the feasibility, acceptability, and potential efficacy of a pain management intervention adapted for older adults with cancer in rural settings.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle, WA, Maury Regional Medical Center, Columbia,, TN, Brown University - Lifespan Cancer Institute,
Abstract
Validation of a whole exome/whole transcriptome liquid biopsy assay with correction for clonal hematopoiesis.Org: Caris Life Sciences, Irving, TX, Barbara Ann Karmanos Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lombardi Comprehensive Cancer Center, Georgetown University Medical School,
Abstract
Combination of 5-FU plus KRAS G12D inhibitor MRTX1133 against human colorectal and pancreatic cancer cells and the affects on inhibition of pERK and immune-stimulatory cytokine patterns in in KRAS G12D and KRAS G12V tumor cells.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI, Legorreta Cancer Center at Brown University, Brown University, Providence, RI,
Abstract
The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Cincinnati Medical Center, Brown University - Lifespan Cancer Institute, Hoag Family Cancer Institute and University of Southern California,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,